research Teneligliptin-induced hair loss: A case report
Increasing Teneligliptin on his own caused a man's hair loss, which stopped when he ceased the medication.
Search
for
Sort by
Research
30 / 1000+ results
research Repurposing of Linagliptin Similar FDA Approved Drugs as Antidiabetic Agents
Pranlukast and mirabegron may work as new diabetes drugs.
research Linagliptin-Associated Alopecia and Bullous Pemphigoid
Linagliptin may cause hair loss and skin blisters.
research Increased risk of hair loss with GLP-1 receptor agonists: A real-world multicenter TrinetX cohort study
research Increased risk of telogen effluvium with tirzepatide compared to other weight-loss medications: a retrospective cohort TriNetX database study
research Alopecia areata universalis nach Sitagliptin-Einnahme
A patient's hair loss may be linked to their diabetes medication, Sitagliptin.
research DPP-4 inhibition with linagliptin ameliorates the progression of premature aging in klotho−/− mice
Linagliptin slows down premature aging in certain mice.
research Formulation of Deformable Liponiosomal Hybrid of Repaglinide: In vitro Characterization and Evaluation of the Anti-Diabetic Effect
Repaglinide-loaded liponiosomal hybrids improve blood sugar control and insulin release better than regular Repaglinide.
research The use of oral pioglitazone in the treatment of lichen planopilaris
Pioglitazone may help treat lichen planopilaris, but more research is needed.
research Good efficacy achieved by telitacicept in treatment of systemic lupus erythematosus with alopecia areata
Telitacicept effectively improved hair regrowth in a woman with lupus and alopecia.
research EFFECTS OF LIRAGLUTIDE ON VISCERAL ADIPOSITY INDEX IN WOMAN OF REPRODUCTIVE AGE WITH PREDIABETES
Liraglutide with metformin reduces body fat and improves blood sugar control better than metformin and inositol in women with prediabetes.
research Lichen planopilaris treated by the peroxisome proliferator activated receptor-γ agonist pioglitazone: Lack of lasting improvement or cure in the majority of patients
Pioglitazone usually doesn't effectively treat or cure lichen planopilaris.
research La FDA aprueba Litfulo® (ritlecitinib) para el tratamiento de la alopecia areata grave en adolescentes y adultos
The FDA approved Litfulo® for treating severe alopecia areata in people aged 12 and older.
research Blockbuster Weight-Loss Drugs Not Tied to Suicidality, Studies Show
Weight-loss drugs are not linked to suicidal thoughts.
research Tofacitinib for the treatment of lichen planopilaris: A case series
Oral tofacitinib can significantly improve recalcitrant lichen planopilaris.
research Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin
Combining liraglutide and metformin helps obese women with PCOS who didn't lose weight on metformin alone to lose more weight.
research Exploring the Role of GLP ‐1 Agents in Managing Diabetic Foot Ulcers: A Narrative and Systematic Review
GLP-1 receptor agonists may help manage and prevent diabetic foot ulcers.
research Dermatological adverse reactions and therapeutic potential of semaglutide, liraglutide and tirzepatide: Analysis of UK pharmacovigilance data and literature review
GLP-1 receptor agonists can help skin conditions but may cause hair loss and other skin issues.
research Tebentafusp-tebn (Kimmtra®)
Tebentafusp-tebn improves survival rates in uveal melanoma patients but has common side effects like rash and fatigue.
research A 12-week treatment with the long-acting glucagon-like peptide 1 receptor agonist liraglutide leads to significant weight loss in a subset of obese women with newly diagnosed polycystic ovary syndrome
Liraglutide caused significant weight loss in some obese women with PCOS, especially those with severe obesity and insulin resistance.
research Strategie di targeting farmacologico delle beta-cellule pancreatiche per la terapia del diabete mellito di tipo 2
Targeted drug delivery to pancreatic beta-cells can improve type 2 diabetes treatment.
research Risk of Alopecia Areata with Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss
GLP-1 agonists may increase the risk of hair loss.
research Hair Loss in Patients on Glucagon-Like Peptide 1 Receptor Agonists: Understanding Risks and Managing Outcomes
Glucagon-like peptide 1 receptor agonists (GLP-1RAs), used for type 2 diabetes and weight loss, have been linked to hair loss, particularly with semaglutide and tirzepatide, though causality is not established. Evidence primarily comes from pharmacovigilance databases and retrospective studies, with no prospective, controlled studies specifically addressing this issue. Rapid weight loss from these drugs may cause telogen effluvium, a potential mechanism for hair loss. As prescriptions rise in Europe, cases may increase, necessitating further research into causality and risk factors. Clinicians should inform and monitor patients for potential hair loss.
research Treatment of insulin resistance with tirzepatide leading to improvement of hair loss
Tirzepatide may improve hair loss by reducing insulin resistance.
research Efficacy and safety of SGLT2 inhibitor on insulin resistance and hyperglycemia in Werner syndrome—A case report
Dapagliflozin improved blood sugar control in a man with Werner syndrome without side effects.
research Treatment of Lipodystrophy with Troglitazone
Troglitazone increases subcutaneous fat in lipodystrophy patients.
research GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects
GLP-1 receptor agonists, like Dulaglutide, Liraglutide, and Semaglutide, have potential benefits beyond the pancreas, including neuroprotection, pain suppression, cardiovascular protection, obesity management, and cancer treatment, but there are concerns about pancreatitis and pancreatic cancer risks.
research Non-clinical safety evaluation and risk assessment to human of aleglitazar, a dual PPAR α/γ agonist, and its major human metabolite
Aleglitazar and its major metabolite are safe enough to proceed to Phase 3 clinical trials.
research Structure optimization of tetrahydropyridoindole-based aldose reductase inhibitors improved their efficacy and selectivity
Optimizing the structure of a specific compound greatly improved its effectiveness and precision for treating diabetic complications.
research Semaglutide as a Cornerstone Therapy in Obesity: Clinical and Pharmacological Insights
Semaglutide is an effective weekly treatment for obesity, promoting weight loss and improving health, despite some side effects.